Skip to content
contact@indiamedicine.orgLogin / Register
IMSDA
  • Home
  • About Us
  • Drugs
  • News
  • Knowledge
  • Members
  • Contact Us
Search for:
Menu Close
  • Home
  • About Us
  • Drugs
  • News
  • Knowledge
  • Members
  • Contact Us

Pirfenex

  1. Home>
  2. News>
  3. Pirfenex

Pirfenidone for Post-COVID Pulmonary Fibrosis: 2025–2026 Latest Research & Real Result

  • Post published:March 1, 2026
  • Post category:News

New Findings in Pulmonary Fibrosis and Post-COVID Lung Disease Pulmonary fibrosis after COVID-19 is leaving thousands of patients struggling to breathe every day. Many are desperately searching for treatments that…

Continue Reading Pirfenidone for Post-COVID Pulmonary Fibrosis: 2025–2026 Latest Research & Real Result

Recent Posts

  • CDSCO Mandates Pharma Companies to Maintain Adverse Event Reporting Systems
    September 1, 2026/
    0 Comments
  • India Pushes for Pharma Market Access in Argentina and Brazil
    August 31, 2026/
    0 Comments
  • India’s Pharma Ambitions Meet Regulatory Capacity: What Buyers Should Know
    August 30, 2026/
    0 Comments

Follow Us

IMSDA

Recent Posts

  • CDSCO Mandates Pharma Companies to Maintain Adverse Event Reporting Systems
  • India Pushes for Pharma Market Access in Argentina and Brazil
  • India’s Pharma Ambitions Meet Regulatory Capacity: What Buyers Should Know
  • CBN and PHARMEXCIL Sign MoU on Controlled Substances Exports
  • Understanding India’s Drug Safety Framework: A 2026 Buyer’s Guide

Contact Info

  • If you want to touch more medicine sales and distribution resources, you could contact us, or join us.
  • Address:2nd Floor, Bhavani CHS, Dadar West, Mumbai, 400028, Maharashtra.
  • Phone:+91 8048111688
  • Email:contact@indiamedicine.orgOpens in your application
  • Website:https://indiamedicine.org/
  • Home
  • About Us
  • Drugs
  • News
  • Knowledge
  • Members
  • Contact Us
© Copyright All Right Reserve